Last reviewed 2026-04-20 · How we verify

Aflibercept Injection

Aflibercept Injection, marketed by the Federation Francophone de Cancerologie Digestive, holds a significant position in the oncology market with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and strong patent protection. However, the primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) (PHASE2, PHASE3)
• 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (PHASE3)
• A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration (PHASE3)
• Clinical Study to Compare Efficacy and Safety of AVT29 and Eylea HD in Participants With Diabetic Macular Edema (PHASE3)
• Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) (PHASE3)
• An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Preterm Babies With Retinopathy of Prematurity in the United Kingdom (UK)
• High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes (PHASE4)
• Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.